HUYA Bioscience International expands senior management team

Recruits Dmitri Kharkevitch as Vice President for Clinical Development

Biopharmaceutical firm HUYA Bioscience has added Dmitri Kharkevitch to its senior management team as Vice President, Clinical Development Oncology. He will support the company's expansion of its clinical development programmes for its lead anti-cancer drug HBI-8000.

Kharkevitch has more than 30 years of experience in oncology which includes 15 years in leadership positions within pharma and biotech covering clinical and medical affairs at Roche, Pfizer, Bristol-Myers Squibb, Vical, Antigenics and MD Anderson Cancer Centre in Houston, TX, US.

He brings experience in all phases of drug development for haematology and solid tumours to the company.

You may also like

Research & Development

HUYA Bioscience and Zhongshan Technology Park form alliance

To accelerate discovery and development of biopharmaceuticals in China
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now